Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuroblastoma Maintenance Therapy Trial Using DFMO
NCT02679144Phase 2Active, not recruiting
- Start
- Feb 2016
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of eflornithine in neuroblastoma. Primary endpoint: Event Free Survival at 2 years. Started Feb 2016; status: active, not recruiting.
02
Drugs
eflornithine
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT02679144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02679144.